Immunocytokines
Open Access
- 31 May 2012
- journal article
- review article
- Published by MDPI AG in Antibodies
- Vol. 1 (1) , 70-87
Abstract
A number of cytokines have shown beneficial effects in preclinical animal models of cancer and chronic inflammatory diseases. However, cytokine treatment is often associated with severe side effects, which prevent the administration of clinically relevant doses in humans. Immunocytokines are a novel class of biopharmaceuticals, consisting of a cytokine moiety fused to monoclonal antibodies or to an antibody fragment, which selectively accumulate at the disease site and thereby enhance the therapeutic effects of cytokines. This review surveys the recent preclinical and clinical advances in the field, with a special focus on the impact of antibody formats, target antigen and cytokine moieties on the therapeutic performance in vivo. We also discuss emerging data about the possibility to combine immunocytokines with other pharmacological agents.Keywords
This publication has 84 references indexed in Scilit:
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic MelanomaClinical Cancer Research, 2011
- A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell CarcinomaClinical Cancer Research, 2011
- Soluble plasma HLA peptidome as a potential source for cancer biomarkersProceedings of the National Academy of Sciences, 2010
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastomaBritish Journal of Cancer, 2010
- Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon AdenocarcinomaClinical Cancer Research, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12British Journal of Cancer, 2007
- Targeting the stromal microenvironment in chronic inflammationCurrent Opinion in Pharmacology, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005